Abstract 1686P
Background
As global cancer cases increase exponentially, the number of caregivers subsequently increases to support patients. Despite being indispensable, the available resource was reserved mainly for patients, undermining the importance of caregivers who also share the struggle and burden. The chronic amount of stress and responsibility that caregivers face leads to impairment of quality of life (QOL). Further, most research that assesses the QOL is mainly conducted in the developed countries with robust palliative care. This comparative study aims to map and explore the status quo of QOL levels from caregivers of cancer patients in Asia. In addition, to investigate the correlation of QOL impairments in caregivers with sociodemographic factors.
Methods
A comprehensive systematic review of the literature was performed through databases with the keywords “cancer”, “caregiver”,” quality of life”, and “Asia” spans from 2004-2024. 371 articles that satisfy eligible criteria were retrieved. A total of 1271 family caregivers for cancer patients who had taken outpatient treatment, finished sociodemographic, and the Caregiver Quality of Life Index-Cancer (CQOLC) survey were included. Gathered CQOLC total scores from 12 countries including Indonesia, Singapore, Malaysia, Turkey, Iran, Jordanian, India, South Korea, China, Taiwan, Japan, and Saudi Arabia dataset, were compared and analyzed for their correlation with sociodemographic factors.
Results
Different distributions of total scores of CQOLC in 12 Asia countries observed with higher CQOLC total scores were scored within the developed countries with mature palliative care systems. Further, varying caregiver determinants including different sociodemographic characteristics could produce impaired QOL such as male gender, parental relationships, certain ethnicity, and late-stage cancer.
Conclusions
Despite sharing cultural context and family-based caregivers, uneven QOL distribution was observed across Asian countries. This study also highlights the potential areas to be improved. Additionally, acknowledging the diversity of values, culture, and socio-demographics significantly helps in creating more optimal interventions to support caregivers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11